RIG Antibody / Protein regulated in glioma, 100 ug

RIG antibody detects Protein regulated in glioma (RIG), a small nuclear protein of approximately 12 kDa composed of 110 amino acids. This protein was originally identified in glioma cell lines, where its expression correlated with tumor cell growth and differentiation state. The UniProt recommended name is Protein regulated in glioma (RIG). Unlike RIG-I (the 102 kDa DExD/H-box helicase involved in antiviral signaling), this RIG protein is a distinct nuclear factor believed to participate in transcriptional regulation and RNA metabolism within glial and neuronal cells.

RIG localizes predominantly to the nucleus and may function as a DNA- or RNA-binding protein that modulates transcriptional output under conditions of metabolic or proliferative stress. Its small size and sequence composition suggest that it acts as an auxiliary nuclear factor rather than a canonical enzyme. Expression analyses from glioma and astrocytoma models indicate that RIG levels can fluctuate during tumor progression, possibly reflecting changes in transcriptional activity, cell cycle control, or differentiation signaling. Overexpression of RIG in some glioma-derived lines has been linked to enhanced proliferation and resistance to apoptotic stimuli, whereas reduced expression can coincide with altered cell morphology or loss of growth capacity.

The RIG gene encodes a compact protein that may influence chromatin accessibility or RNA processing. It is expressed in several tissues but shows highest abundance in neural and glial populations. Its amino acid sequence contains motifs compatible with nuclear localization and RNA recognition, supporting a role in coordinating transcriptional output with cellular stress or growth cues. Although the detailed mechanisms remain under investigation, RIG is thought to act as a nuclear modulator of gene expression relevant to glioma pathogenesis.

At the cellular level, RIG expression has been reported to respond to external stimuli such as serum withdrawal, oxidative stress, and exposure to differentiation agents. These findings suggest that RIG may help cells adapt transcriptionally to environmental or developmental cues. In glioma models, its upregulation is often associated with actively dividing cells, consistent with a role in sustaining nuclear RNA metabolism and growth-associated gene expression programs.

RIG antibody provides a specific reagent for detecting this 12 kDa nuclear protein in cultured cells and tissue extracts. It supports research focused on glioma biology, transcriptional regulation, and nuclear protein function. The antibody can aid in identifying RIG expression patterns in tumor versus normal brain tissue and in exploring nuclear pathways involved in glial differentiation. NSJ Bioreagents provides RIG antibody validated for use in relevant research applications supporting studies in neuro-oncology, transcriptional regulation, and cellular signaling.